Drug intelligence / Profile preview

LCAR-BCDR cells

Development stage
Discontinued
Lead developer
Legend Biotech
Modality
CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration
Intravenous
01

Overview

LCAR-BCDR cells are a universal CAR-T cell therapy developed to target B-cell maturation antigen (BCMA), a protein specifically expressed on mature B lymphocytes and plasma cells. Upon administration, these engineered T cells recognize and kill tumor cells expressing BCMA through immunologic cytotoxicity. The primary indication for LCAR-BCDR is the treatment of relapsed or refractory multiple myeloma. The product is being developed by Nanjing Legend Biotech and is currently in Phase 1 clinical trials[1][2]. As a CAR-T cell therapy, it represents an advanced form of adoptive cell transfer designed to harness the patient’s immune system against hematologic malignancies.

Other names
CAR-T-Second Affiliated Hospital of Xi'an Jiaotong University-multiple myelomaCAR-T Re-treatmentBCMA-targeted CAR-T cell re-treatment
02

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on LCAR-BCDR cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LCAR-BCDR cells.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call